

Desoxyn is a prescription stimulant for ADHD. Learn about its uses, dosage, cost, side effects, and what makes it different in 2026.
Desoxyn (Methamphetamine Hydrochloride) is an FDA-approved prescription medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 and older, and for short-term treatment of obesity when other therapies have failed.
If you've heard the name and have questions — or concerns — you're not alone. Desoxyn is one of the most misunderstood medications in the United States. This guide covers everything you need to know: what it is, how it's used, who makes it, how much it costs, and why it's so hard to find.
Desoxyn is the brand name for Methamphetamine Hydrochloride, a central nervous system (CNS) stimulant in the amphetamine class. Here are the key facts:
Desoxyn was first approved by the FDA decades ago and has been used in clinical practice for a long time. Despite sharing a name with the illicit street drug, prescription Methamphetamine is a carefully dosed, pharmaceutical-grade medication taken under medical supervision at much lower doses than those associated with abuse.
Desoxyn is FDA-approved for ADHD in children aged 6 and older. In practice, it's also used off-label for adults with treatment-resistant ADHD — meaning patients who haven't responded well to first-line medications like Adderall, Vyvanse, or Ritalin.
Desoxyn works by increasing dopamine and norepinephrine in the brain, which helps improve focus, attention, and impulse control.
Desoxyn is also approved as a short-term adjunct for weight loss in patients who haven't responded to diet and exercise alone or to other weight-loss therapies. However, this use is uncommon today due to the availability of newer weight management medications and the risks associated with stimulant use for weight loss.
Desoxyn comes in a single strength: 5 mg tablets, taken by mouth.
Desoxyn is not safe for everyone. You should not take it if you have:
Your doctor should perform a cardiac evaluation before prescribing Desoxyn and screen for tics, Tourette's syndrome, and mental health conditions. Learn more about drug interactions and side effects in our dedicated guides.
Desoxyn is expensive, and it's not covered by most insurance plans.
Most Medicare and commercial insurance plans do not cover Desoxyn. Those that do typically require prior authorization and step therapy — meaning you must try other ADHD medications first.
Ajenat Pharmaceuticals offers a co-pay savings card for eligible commercially insured patients that may reduce costs to as low as $0. Check desoxyn.com for current program details.
For more ways to reduce your costs, see our complete savings guide.
Desoxyn has been in a chronic shortage since 2022. Only two manufacturers currently produce it, DEA production quotas limit supply, and most pharmacies don't stock it due to low demand. The brand has changed hands multiple times — from Recordati to Key Therapeutics to Ajenat Pharmaceuticals.
If you need help finding Desoxyn in stock, Medfinder tracks real-time pharmacy availability so you can check without calling.
Desoxyn is a legitimate, FDA-approved medication that can be life-changing for people with treatment-resistant ADHD. While it carries more stigma than other stimulants, it's prescribed by specialists who have exhausted other options and believe it's the right fit for their patient.
If you're considering Desoxyn or have just been prescribed it, learn about finding a prescriber, understand the potential side effects, and explore alternatives in case you can't fill your prescription.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.